Amid a challenging funding environment post-pandemic, multiple Boston-area biotech startups have shuttered or downsized, including NextRNA Therapeutics. Despite promising science and prior partnerships, financial constraints forced these closures, contributing to significant job losses in the sector. Broader industry trends and dwindling venture capital are eroding the innovation ecosystem, raising concerns about the sustainability of early-stage biopharma ventures.